Compugen (CGEN) to Release Earnings on Monday

Compugen (NASDAQ:CGEN) is projected to post its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Compugen to post earnings of $0.05 per share and revenue of $14.2960 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 2, 2026 at 8:30 AM ET.

Compugen Stock Performance

NASDAQ:CGEN opened at $1.74 on Monday. The firm has a 50-day simple moving average of $1.76 and a 200-day simple moving average of $1.64. Compugen has a one year low of $1.13 and a one year high of $2.38.

Analyst Ratings Changes

A number of analysts have weighed in on CGEN shares. HC Wainwright assumed coverage on Compugen in a report on Wednesday, January 7th. They set a “buy” rating and a $4.00 target price for the company. Wall Street Zen upgraded Compugen from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $4.00.

Institutional Trading of Compugen

Institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its stake in Compugen by 3.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock valued at $2,229,000 after buying an additional 51,565 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Compugen by 1,077.0% during the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after acquiring an additional 359,785 shares during the last quarter. State Street Corp increased its holdings in shares of Compugen by 3.9% during the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after acquiring an additional 14,701 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Compugen by 10.6% in the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 18,929 shares during the last quarter. Finally, Marshall Wace LLP raised its position in shares of Compugen by 135.7% in the 4th quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 61,202 shares during the last quarter. Institutional investors and hedge funds own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.